Author: Ken Dropiewski

AliveCor Announces Dual FDA Clearance of AI Technology That Delivers 35 Cardiac Determinations and First-of-its-Kind Kardia 12L ECG System

Rhythm by Comments are Disabled

World’s First AI to Detect 35 Cardiac Determinations, Including Heart Attack, Using a Reduced LeadsetPowered by this AI, the Pocket-Sized Kardia 12L ECG System Enables Faster, Easier Detection of Life-Threatening Cardiac ConditionsMOUNTAIN VIEW, Calif., June 25, 2024 /PRNewswire/ — AliveCor, the global leader in AI-powered cardiology, today announced the U.S. Food & Drug Administration (FDA) clearance and commercial launch of KAI™ 12L AI technology and the Kardia™ 12L ECG System. This is the world’s first AI that can detect life-threatening cardiac conditions, including heart attacks, using a reduced leadset. The Kardia 12L ECG System, featuring a game-changing patented technology, is the world’s first AI-powered handheld 12-lead electrocardiogram (ECG) system with a unique single-cable design.

Continue Reading

Kardia 12L ECG System Enables Faster, Easier Detection of Life-Threatening Cardiac Conditions Using Reduced Leadset

Pocket-Sized Kardia 12L ECG System

KAI 12L employs multiple deep neural network algorithms, trained and validated on more than 1.75 million ECGs from leading US medical centers. This AI technology can detect 35 cardiac determinations (14 arrhythmias and 21 morphologies), including serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia, using a reduced leadset. KAI 12L can seamlessly integrate with compatible devices, including the Kardia 12L ECG System, expanding critical access to accurate heart data within a broad range of healthcare settings.

“Not only is it the first FDA-cleared AI that can detect a heart attack on a reduced leadset, but it also returns determinations for our broadest range of conditions yet,” said Priya Abani, CEO of AliveCor. “Paired with our pocket-sized Kardia 12L ECG System, this offering is poised to disrupt traditional care pathways and represents a leap forward in cardiac care.”
Kardia 12L ECG System is an innovative solution that requires only a single cable with 5 electrodes to acquire 8 high quality diagnostic bandwidth leads. Conventional 12-lead ECG machines are the standard of care for detecting and diagnosing many heart conditions, but their availability can be limited due to their size and complexity. Using advanced KAI 12L and a reduced leadset, Kardia 12L offers outstanding clinical efficiency and performance substantially equivalent to state-of-the-art ECG analysis solutions. Its speed and simplicity assists healthcare providers in rapid disease detection and enhancing patient experience. “The AI innovations in the Kardia 12L ECG System offer healthcare providers a clinically-validated handheld 12-lead ECG system and expands this critical technology into more resource-limited settings,” said Dr. Stavros Stavrakis, MD, PhD, Professor of Medicine, Division of Cardiology at the University of Oklahoma Health Sciences Center. “By streamlining the process of recording a 12-lead ECG, Kardia 12L has significant implications for rapid ECG diagnosis in clinical practice.”Kardia 12L is battery-operated, weighs just 0.3 pounds and can fit in a pocket – making it significantly smaller, more portable and more convenient than conventional 12-lead ECG machines. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler to use than standard 12-lead ECG machines. These features put 12-lead ECG data within reach of more healthcare providers than ever before in a variety of healthcare facilities and acute settings, including primary and urgent care offices, employer clinics, and other under-resourced or rural venues.For healthcare providers interested in purchasing a Kardia 12L, please visit alivecor.com/products/kardia12L.About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With over 250 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.Media ContactsSu Leeslee191@alivecor.com(562) 544-4634Ben Rickles[email protected](404) 502-6766SOURCE AliveCor, Inc.

Continue Reading →

Avive Solutions, Inc. Welcomes Mark Peters as New Vice President of Sales

Financial by Comments are Disabled

SAN FRANCISCO, June 25, 2024 /PRNewswire/ — Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Mark Peters as their new Vice President of Sales. A highly-regarded sales leader in the AED, medical device, and public safety industries, Peters brings with him a wealth of experience building and leading high-performing sales teams and an impressive track record of driving commercial and strategic growth.
“I am thrilled to join Avive’s leadership team and bring both my professional experience and personal passion for the proliferation of AEDs to the company at this exciting time in their journey,” said Peters. “For years, there have been millions of AEDs out in the world with very little change in Sudden Cardiac Arrest survival rates. Avive is the only AED company innovating on new ways to change the outlook for Sudden Cardiac Arrest response, now and into the future. It has been incredible to watch the founders take their mission to democratize defibrillation from concept to reality, with the first truly new technological advancement in the AED space in over 20 years.”
After losing a close friend to Sudden Cardiac Arrest (SCA) in 2000, Peters suffered Sudden Cardiac Arrest himself in 2009 and was fortunate to survive, an event that altered the trajectory of his life. Since then, he has devoted his career to increasing the presence of this lifesaving device throughout the nation, beginning with a role as an Account Executive on the sales team at AED manufacturer Cardiac Science. Over the subsequent 8.5 years, Peters ascended the sales ranks quickly, culminating in a role as Senior Director of U.S. Distribution and Strategic Growth, overseeing a high-performing national sales team and the company’s channel expansion strategy. Peters and his team achieved exemplary performance and increased the company’s market share significantly during his tenure, culminating in an acquisition by ZOLL Medical in 2019. Since then, Peters has held a variety of executive sales leadership roles in the public safety field, showcasing his expertise in sales and go to market strategy, market growth, and strategic partnerships in service of making public safety and lifesaving tools and technologies more readily available throughout the nation.
“We are excited to have Mark join our leadership team at Avive, where he not only brings tremendous domain expertise from his time at Cardiac Science, but also a proven track record of building high-performing and customer centric sales teams,” said Sameer Jafri, Avive’s co-founder and CEO. “He is taking the leadership reins of our sales team at the perfect time in our company’s journey, as he will play a key role in continuing to drive and catalyze our rapid commercial ramp in the U.S.”
As Peters takes the helm of the Sales team at Avive Solutions, Inc., he is singularly focused on developing the most knowledgeable and customer-centric, consultative sales team in the industry, while keeping Avive’s mission to increase the presence of lifesaving AEDs and save more lives front and center at all times. “Simply put, Avive is mission-driven and mission-first,” he said. “The proliferation of AEDs over the past couple of decades has unfortunately not correlated to increased SCA survival rates. Now, Avive is fundamentally changing the way the entire AED industry thinks about response and survival. My mission here will be to drive market adoption in key verticals to make more Avive AEDs accessible to everyone, ultimately helping us have a tangible, positive impact on SCA survival rates and saving countless lives.”
About Avive Solutions, Inc.
Avive Solutions is a new kind of AED company, revolutionizing Sudden Cardiac Arrest response with an innovative platform that brings together a 21st-century AED device and a first-of-its-kind software solution. With their award-winning product, the Avive Connect AED, Avive is the first new company to bring an AED to market in the U.S. in over 20 years. Focused on portability, accessibility, and connectivity, the Avive Connect AED is one of the most advanced products in the industry. Additionally, Avive’s software solutions not only make owning and managing AEDs simple, they also deliver a comprehensive cardiac arrest response solution to communities, with the goal of increasing bystander intervention, decreasing time-to-defibrillation, and transmitting valuable data to the people who need it, when they need it. Founded in 2017, Avive is on a mission to empower bystanders, first responders, and 911 telecommunicators to provide lifesaving care as quickly and easily as possible. Learn more at avive.life.
Media Contact:Kyle Noble[email protected] (415) 287-6881
SOURCE Avive Solutions, Inc.

Continue Reading →

Data Supporting Nanox.AI Cardiac Solution to Be Presented at 19th Annual Meeting of the Society of Cardiovascular Computed Tomography

Radiology by Comments are Disabled

PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C. The studies are being presented by esteemed institutions Brigham & Women’s Hospital, Einstein Jefferson Medical Center, Corewell Health, Massachusetts General Hospital and Beilinson Medical Center. Nanox AI’s Cardiac Solution (HealthCCSng) utilizes medical imaging data from routine chest CT scans to automatically quantify coronary artery calcium (CAC) levels. CAC is known as a strong predictor of future cardiovascular events; patients in the highest CAC category are up to 6x more likely to suffer cardiac events. The abstract details are as follows: Title: The Frequency, Prevalence, And Outcomes of Incidentally Detected Coronary Artery Calcium Using Artificial Intelligence Analysis Among Patients with Immune Mediated Inflammatory Diseases (Best Abstract Award Finalist)Lead Author: Brittany Weber, Brigham & Women’s HospitalAbstract number: 2024-A-817-SCCTPresentation date and time: Saturday, July 20, 10:30 AM, Liberty I-M Title: Optimizing Preventive Cardiology: Harnessing AI for Early Detection of Coronary Artery DiseaseLead author: Dr. Chiduzie Madubata, Einstein Jefferson Medical CenterAbstract number: 2024-A-573-SCCTPresentation date and time: Friday, July 19, 9:30AM – 10:15AM, Exhibit Hall Title: AI Empowering Early Detection of CAD Patients for Improved Cardiac CareLead author: Dr. David Langholz, Corewell HealthAbstract number: 2024-A-641-SCCTPresentation date and time: Friday, July 19, 9:30AM – 10:15AM, Exhibit Hall Title: Artificial-intelligence Based Detection of Coronary Artery Calcium on Chest CT to Enhance Cardiovascular Risk Assessment of Individuals with Elevated Lipoprotein (a)Lead author: Milena Petranovic, Massachusetts General HospitalAbstract number: 2024-A-820-SCCTPresentation date and time: Friday, July 19, 9:30AM – 10:15AM, Exhibit Hall Title: Opportunistic Screening of Coronary Artery Calcification On Non-gated Conventional CT Scans Using Artificial IntelligenceLead author: Dr. Ashraf Hamdan, Beilinson HospitalAbstract number: 2024-A-532-SCCTPresentation date and time: Saturday, July 20, 9:30AM – 10:15AM, Exhibit Hall  Throughout SCCT, Nanox AI’s representative will also be available for meetings in the Honeysuckle Meeting Room. You can schedule a meeting here. About Nanox AINanox AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox AI’s solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai. About NanoxNanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision. Contacts Media Contact:Ben ShannonICR WestwickeNanoxPR@icrinc.com Investor Contact:Mike CavanaughICR Westwickemike.cavanaugh@westwicke.com

Continue Reading →

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

Financial by Comments are Disabled

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company’s US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. “We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy,” said Kevin Hykes, President and CEO of CVRx. “Robert is well-known and respected within the heart failure community and has extensive experience building global sales organizations, launching novel heart failure therapies, and delivering results. He will be invaluable as we accelerate our commercial momentum.” John brings over 25 years of sales leadership experience in the medical device industry, with a strong track record of building high-performing sales teams. Most recently, he served as Divisional Vice President and General Manager of Cardiac Rhythm Management EMEA at Abbott, where he led a global business unit spanning over 90 countries. Prior to this role, he was first Senior Vice President, then the Divisional Vice President of the Heart Failure business, responsible for integrating the Thoratec and CardioMEMs businesses and leading the commercial teams for St. Jude, then at Abbott post-acquisition. Prior to the acquisition, John held multiple commercial leadership positions at St. Jude Medical across the Cardiac Rhythm, Electrophysiology, Capital, Structural Heart, Vascular and Heart Failure businesses. Prior to Abbott/St. Jude, John held commercial roles at Medtronic, Guidant and Pfizer. He holds a Bachelor of Science from the University of North Texas and a Master of Arts in Human Resources Management from the University of Alabama, Tuscaloosa. “I am excited to join CVRx at this pivotal time for the company and the patients we serve,” said Robert John. “Throughout my career, I have been passionate about bringing innovative therapies to market that can significantly improve patient outcomes. CVRx’s Barostim therapy is a truly revolutionary technology with the potential to transform the treatment of heart failure. I look forward to working with the talented CVRx team to make this groundbreaking therapy available to more patients and drive the next phase of the company’s growth.” About CVRx, Inc. CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike VallieICR Westwicke443-213-0501ir@cvrx.com Media Contact: Laura O’NeillFinn Partners402-499-8203laura.oneill@finnpartners.com

Continue Reading →

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

Peripheral/Endo by 0 comments

June 24, 2024 08:32 AM Eastern Daylight Time LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside (NR) supplementation for people with peripheral artery disease (PAD). This study was […]

Continue Reading →

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Coronary/Structural Heart by 0 comments

June 24, 2024 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Alnylam Reports Positive […]

Continue Reading →

HeartFocus Joins Butterfly Garden to Develop Software Enabling Any Healthcare Professional to Conduct Lifesaving Echos on Butterfly’s Imaging Platform

Financial Radiology by 0 comments

June 24, 2024 07:00 AM Eastern Daylight Time BORDEAUX, France–(BUSINESS WIRE)–HeartFocus, the revolutionary, AI-driven heart exam software by DESKi, a provider of automated, accurate, and data-driven image analysis tools today announced it has joined Butterfly Garden, an artificial intelligence (AI) Marketplace launched by Butterfly Network, Inc., (“Butterfly”) (NYSE: BFLY) a digital health […]

Continue Reading →

Heart Hospital of New Mexico at Lovelace Medical Center and GE HealthCare Collaborate to Install the First Allia IGS Pulse Electrophysiology Lab in the United States for Minimally Invasive Cardiovascular Procedures

Rhythm by 0 comments

ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Today Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (Nasdaq: GEHC) announced HHNM as the first location in the United States to install GE HealthCare’s latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and […]

Continue Reading →

MemorialCare Heart & Vascular Institute at Long Beach Medical Center is First Hospital in Southern California to Perform Transcatheter Aortic Valve Implantation with Navitor Titon 35mm Valve

Coronary/Structural Heart by Comments are Disabled

This is the first 35mm size valve implantation giving those with large native aortic valves at high-risk a minimally invasive option – avoiding open heart surgeryLONG BEACH, Calif., June 21, 2024  /PRNewswire/ — Yesterday, MemorialCare Heart & Vascular Institute at Long Beach Medical Center was the first hospital in Southern California to implant a 35mm Abbott Titan Navitor Valve during a Transcatheter Aortic Valve Implantation (TAVI) procedure. The TAVI procedure is crucial for patients who have severe aortic stenosis and are at extreme risk for open-heart surgery. This offers a minimally invasive approach which shortens hospital stays, reduces risk of infection and lessens recovery time.

Continue Reading

Titan Navitor Valve Team from MemorialCare Heart and Vascular Institute at Long Beach Medical Center

“We are very proud of Dr. Anthony Chyou and Dr. Ali Khoynezhad for leading us through this transformational time of our heart and vascular institute,” says David Shavelle, M.D., FACC, chief of cardiology, MemorialCare Heart & Vascular Institute; medical director, adult cardiology & interventional lab, MemorialCare Heart & Vascular Institute at Long Beach Medical Center. “We have always taken pride in creating an environment where our patients are given personalized treatment. The Navitor Titan 35mm Valve allowed us to provide a minimally invasive treatment option to a high-risk patient with severe aortic stenosis.”

The Navitor valve is one of the newest heart valve devices approved by the U.S. Food and Drug Administration for TAVI, also known as Transcatheter Aortic Valve Replacement (TAVR). This device is different from other heart valve replacement valves on the market due to improved blood flow (hemodynamic) performance and ease of use.
“The intuitive design of the Navitor TAVI System allows more patients who normally would not be viable candidates for a Transcatheter Aortic Valve Replacement procedure access to a valve replacement,” says Optum partnering physician Anthony Chyou, M.D., who is also an interventional cardiologist at MemorialCare Heart & Vascular Institute at Long Beach Medical Center. “Patients with large native aortic valves and severe aortic stenosis valve disease may not have been able to receive treatment as prior TAVI valves were not large enough to accommodate their anatomy.”Heart valve disease limits the ability of the heart to pump blood through the entire body. The Navitor TAVI System has been tested and shown to greatly improve the blood flow of patients with symptomatic severe aortic stenosis, helping their hearts resume to normal, healthy blood flow performance quickly.”MemorialCare is dedicated to state-of-the-art, patient-centric care to our community, and this ‘first in the region’ procedure is a testament to our continued commitment to excellent patient care,” says Ali Khoynezhad, M.D., director, aortic and arrythmia surgery, MemorialCare Heart & Vascular Institute at Long Beach Medical Center.The Navitor TAVI System has been rigorously tested and proven to yield positive 30-day outcomes in patients with symptomatic severe aortic stenosis, including a 0% chance of moderate or severe paravalvular leak (PVL), 1.9% chance of all-cause mortality, 1.9% chance of disabling stroke, and 4.2% chance of major vascular complications, proving its remarkable safety and effectiveness in TAVR procedures.About MemorialCare Long Beach Medical Center:MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as “Best Hospital” for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit memorialcare.org/LongBeach.SOURCE MemorialCare Long Beach Medical Center

Continue Reading →

At the SIRM Congress 2024 in Milan, ESAOTE presents the brand-new MyLab™E80, an E-series ultrasound device designed for professionals dealing with more complex clinical cases

Radiology by Comments are Disabled

The unveiling took place at the Esaote stand (I-03), where industry professionals could find out more about the features and performance of the new system, throughout the Congress. MILAN, June 21, 2024 /PRNewswire/ — Esaote – a leading Italian company in the field of medical imaging – has unveiled its new MyLab™E80 ultrasound device to the world of radiology. The unveiling took place at the 51st SIRM Congress 2024 (Allianz MiCo Convention Center, Milan – Stand I-03), the first time the three scientific societies in the field of radiology (SIRM, AIMN, AIRO) have come together for their first joint Congress, entitled “The Next Generation”. 

Continue Reading

The new Esaote MyLab™E80 ultrasound device

Another step forward in terms of innovation, MyLab™E80 is the first ultrasound system in Esaote’s brand-new E series. The ‘E’ stands for Expertise, referring to a series of devices designed for professionals who deal with more complex clinical cases, where diagnostic certainty and clinical efficiency play a decisive role.

This ultrasound scanner guarantees intuitive workflow management, with advanced A.I.-powered automation features to speed up repetitive operations and simplify complex functions. Doctors can therefore conduct more thorough examinations based on images with a very high level of detail. The system also comes with fusion imaging technology, for the assessment of liver disease and breast lesions.
MyLab™E80 integrates the Augmented Insight™ functions of the MyLab™X90 and provides users with options of a conventional or touchscreen control panel, in line with the innovative selection launched in the A Series. “The agile and fast MyLab™E80 and its versatile and mobile advanced features embodies our new vision as part of our ongoing commitment to providing high-quality healthcare. We have therefore improved the reproducibility, efficiency and diagnostic accuracy of our ultrasound scanners,” stated Mariagrazia Bella, Marketing Director for Italy.  “MyLab™E80 is designed to adapt to any healthcare environment. With five probe connectors and custom configurations, it’s ideal for both routine and advanced examinations. The battery offers autonomous scanning at full power, while the modern touch panel simplifies cleaning procedures, ensuring adaptability even in the most demanding environments.”MyLab™E80 completes the renewal of the range of ultrasound scanners developed by Esaote, alongside the MyLab™X90, MyLab™A70 and MyLab™A50. In line with its new brand identity and slogan of “Health with Care”, Esaote confirms its mission and the sense of care and empathy with which it approaches its everyday work, to improve people’s well-being.  www.esaote.com Esaote Group Leader in medical imaging (ultrasound, MRI, software to manage the diagnostic process). At the end of 2023, the Group had 1,250 employees, half of whom in Italy. With facilities in Genoa and Florence, and its own production and research units in Italy and the Netherlands, Esaote maintains a presence in over 100 countries. www.esaote.com© Copyright Esaote 2024Photo – https://mma.prnewswire.com/media/2442819/Esaote_SpA.jpgLogo – https://mma.prnewswire.com/media/2323931/4771337/ESAOTE_Logo.jpg

Continue Reading →
1 … 240 241 242 243 244 … 1,331